NCT02266719
Clinical Outcomes and Radiation Safety After Endovascular Repair of Complex AAAs Using Fenestrated- Branched Devices
Enrolling by Invitation
NAAges 18+InterventionalTreatmentCarlos TimaranInvestigator-initiated
~750 participants
Updated 2026-05-12 on ClinicalTrials.gov
What's tested:Fenestrated CMDType I - III TAAAArch cohort
At a glance
Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluate safety endovascular treatment of juxtarenal, suprarenal, thoracoabdominal and arch aortic aneurysms using fenestrated/branched investigational devices.
Measured over 30 days
+1 more outcome measured
Conditions
Where it's being run
4 sites across 2 statesGeorgia3
Texas1
Study leadership
- Carlos H. Timaran, MD · PRINCIPAL_INVESTIGATOR · Emory University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Evaluate safety endovascular treatment of juxtarenal, suprarenal, thoracoabdominal and arch aortic aneurysms using fenestrated/branched investigational devices.30 days
Primary safety will be defined as the proportion of subjects who experience a major adverse event (MAE) at 30-days or during hospitalization if this exceeds 30 days.
- Evaluate effectiveness endovascular treatment of juxtarenal, suprarenal, thoracoabdominal and arch aortic aneurysms using fenestrated/branched investigational devices.12-months
For primary effectiveness endpoint, treatment success will be analyzed as the proportion of patients to achieve treatment success at 12-months.